Novo Nordisk's FLORAL Study Bets on the Long Game for Etavopivat in Sickle Cell Disease

Most clinical trials ask a sharp, short question: does the drug beat placebo over a few months? Novo Nordisk's FLORAL study (ClinicalTrials.gov identifier NCT06609226) asks a slower and arguably more important one: when people who already responded to a drug keep taking it for years, does it stay safe and keep working? FLORAL is a Phase 3, open-label, multi-center rollover trial for etavopivat, an oral medicine in development for inherited blood disorders. It began enrolling on January 10, 2025, was last updated on June 10, 2026, and is currently recruiting up to 480 participants.

The short version is this. A rollover study takes patients who completed a prior etavopivat trial and offers them continued treatment, so the sponsor can characterize what happens over the long haul. That is exactly what FLORAL does. Its full name describes it plainly: an open-label, multi-centre rollover study to characterise the long-term safety and efficacy of etavopivat in adults, adolescents, and children who have sickle cell disease or thalassaemia and who completed a treatment period in an earlier etavopivat study. The study is designed to run for up to 264 weeks, roughly five years, though Novo Nordisk notes it will end earlier in any country where etavopivat wins approval.

What sickle cell disease and thalassemia actually are

Both conditions FLORAL targets are inherited problems with hemoglobin, the protein inside red blood cells that ferries oxygen around the body. In sickle cell disease, a genetic change makes hemoglobin prone to clumping when oxygen is low, which warps red cells into rigid, sickle shapes. Those misshapen cells get stuck in small blood vessels, triggering excruciating pain crises, organ damage, and chronic anemia because the fragile cells break apart too soon. Thalassemia is a different hemoglobin defect: the body simply does not make enough functional hemoglobin, so patients run chronically anemic and many become dependent on regular blood transfusions to survive.

Think of a red blood cell as a delivery van for oxygen. In sickle cell disease the vans keep crumpling into shapes that jam the roads; in thalassemia the fleet is too small to make the deliveries. Etavopivat is designed to tune up the cellular machinery so the red cells work better and last longer, which is why a single drug can be studied across both disorders at once.

Why the trial design is unusually broad

FLORAL stands out for how wide it casts its net. The enrollment spans an unusual age range, accepting participants from as young as 2 years old with no upper age limit, and it covers multiple distinct patient groups within a single protocol. The registry lists experimental arms for patients 12 and older with sickle cell disease, patients 12 and older with transfusion-dependent sickle cell disease, patients 12 and older with transfusion-dependent thalassemia, those with non-transfusion-dependent thalassemia, and a separate arm for children aged 2 to under 12 with sickle cell disease. Participants receive an oral dose of one of three formulations the registry labels etavopivat A, B, or C.

This is a non-randomized, open-label design with no masking, which is appropriate for a long-term safety study where everyone is meant to receive active drug. The trade-off is that an open-label rollover cannot, by itself, prove efficacy the way a blinded, placebo-controlled study can; its job is to extend the observation window and watch for problems and durable benefit over years rather than to deliver a fresh placebo-controlled verdict.

What the trial is measuring

FLORAL's primary endpoints are squarely about safety over the long term. The registry lists the number of treatment-emergent adverse events and the number of adverse reactions, each reported separately for every indication and age group, measured from the study's baseline out to as far as week 316. That granular, per-group safety accounting is the heart of a rollover study: regulators want to know not just whether a drug is safe on average, but whether it is safe in a 4-year-old with sickle cell disease as well as in a transfusion-dependent adult with thalassemia, because those populations can respond very differently.

It is worth dwelling on why a rollover study earns its own registration rather than being folded into the parent trials. Inherited blood disorders are lifelong conditions, and any chronic therapy will be taken not for the few months of a pivotal study but potentially for decades. Regulators and clinicians therefore need exposure data measured in years to understand cumulative risks, the durability of benefit, and whether tolerability erodes over time. By gathering all the eligible patients who completed earlier etavopivat studies into one continuing program, FLORAL builds the long-term evidence base that a chronic oral drug ultimately needs, and it does so without forcing patients who were already responding to come off treatment, an ethical consideration that rollover designs are partly meant to address.

What a strong FLORAL result would mean

The study's estimated primary completion date is December 30, 2030, so this is a genuinely long-horizon effort. A reassuring readout would show a clean, consistent safety profile across all the age groups and disease subtypes, with no troubling signal emerging as exposure stretches into multiple years, alongside evidence that the hematologic benefits patients saw in the original trials persist rather than fade.

The strategic context matters too. Sickle cell disease has lately been dominated by headlines about one-time gene-editing therapies, which are powerful but complex, expensive, and require demanding conditioning regimens. An oral, once-daily pill that meaningfully improves red-cell health would occupy a very different and broadly accessible niche, especially for the global pediatric population that bears much of the sickle cell burden. FLORAL will not, on its own, win an approval; it is the durability check that sits behind the pivotal data. But by deliberately enrolling children as young as 2 and following them for years, Novo Nordisk is signaling that it intends etavopivat to be a long-term, real-world maintenance therapy, and FLORAL is where that ambition gets stress-tested.